Vahedi and colleagues review the mechanisms shaping the epigenetic landscape of CD4 + and CD8 + T cells during development and differentiation.

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

A bold funding initiative aims to help scientists predict a T cell’s target antigens, with implications far beyond cancer ...

The innovative system merges two previously separate streams of biological data: gene activity at the single-cell level and ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...

A discovery published in Nature Immunology has shed light on why the immune system is less aggressive toward self-antigens, ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo” or the "Company”) an innovative immunotherapy company seeking to ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Immunostimulant therapy using agonistic cytokines or activating antibodies has been associated with off-target side effects, failure to preferentially activate cytotoxic lymphocytes (CTLs) over ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...

CD8-positive T cells are a critical subpopulation of MHC class I-restricted T cell and are mediators of adaptive immunity. They include cytotoxic T cells, which are important for killing cancerous ...